SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-22-014127
Filing Date
2022-09-01
Accepted
2022-09-01 16:31:02
Documents
12
Period of Report
2022-08-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20220829x8k.htm   iXBRL 8-K 41660
  Complete submission text file 0001558370-22-014127.txt   162497

Data Files

Seq Description Document Type Size
2 EX-101.SCH plx-20220829.xsd EX-101.SCH 3259
3 EX-101.LAB plx-20220829_lab.xml EX-101.LAB 16020
4 EX-101.PRE plx-20220829_pre.xml EX-101.PRE 10765
6 EXTRACTED XBRL INSTANCE DOCUMENT plx-20220829x8k_htm.xml XML 4864
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 221221310
SIC: 2836 Biological Products, (No Diagnostic Substances)